David W. Vredevoogd
Amsterdam, NH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
Inhibition of TBK1/IKKε mediated RIPK1 phosphorylation sensitizes tumors to immune cell killing.
Journal: Cell death discovery
Published: May 23, 2025
TMED inhibition suppresses cell surface PD-1 expression and overcomes T cell dysfunction.
Journal: Journal for immunotherapy of cancer
Published: August 09, 2024
TRAF2 and RIPK1 redundantly mediate classical NFκB signaling by TNFR1 and CD95-type death receptors.
TRAF2 and RIPK1 redundantly mediate classical NFκB signaling by TNFR1 and CD95-type death receptors.
Journal: Cell death & disease
Published: April 30, 2024
Multimodal stimulation screens reveal unique and shared genes limiting T cell fitness.
Journal: Cancer cell
Published: July 07, 2023
Heterogeneity in functional genetic screens: friend or foe?
Journal: Frontiers in immunology
Published: February 09, 2023
Author Correction: Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.
Journal: Nature communications
Published: February 07, 2023
The (re)discovery of tumor-intrinsic determinants of immune sensitivity by functional genetic screens.
Journal: Immuno-oncology technology
Published: June 27, 2022
An adverse tumor-protective effect of IDO1 inhibition.
Journal: Cell reports. Medicine
Published: April 01, 2022
RNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cells.
Journal: Cell reports. Medicine
Published: October 22, 2021
Predictive Immune-Checkpoint Blockade Classifiers Identify Tumors Responding to Inhibition of PD-1 and/or CTLA-4.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 29, 2020
Last Updated: 09/26/2026